Overall, the results demonstrated that the antitumour effects induced by AT9283 recapitulated the MKK3 depletion effects [6–8, 11], suggesting that AT9283 is an MKDMA compound in tested CRC lines. The gene discussed is MAP2K3; the disease is colorectal carcinoma.